(TNS) — The FDA has issued a warning to consumers that it has found evidence of counterfeit versions of a popular weight-loss drug in the supply chain.

The U.S. Food and Drug Administration said the fake Ozempic (semaglutide) is not manufactured by Novo Nordisk and includes counterfeit needles in the 1mg injection.

The FDA said it “has seized thousands of units of the product.”

The counterfeit versions, the FDA said, have the lot number NAR0074 and serial number 430834149057.

“FDA and Novo Nordisk (manufacturer of Ozempic) are testing the seized products and do not yet have information about the drugs’ identity, quality, or safety,” the FDA said.

Because the needles are counterfeit, the FDA said, “the sterility of the needles cannot be confirmed, which presents an increased risk of infection for patients who use the counterfeit products. Based on analyses completed to date, other confirmed counterfeit components within the seized products are the pen label, accompanying health care professional and patient information, and carton.”

There have been five “adverse events” linked to the counterfeit drug but the FDA said none were “serious and are consistent with known common adverse reactions to authentic Ozempic, which are nausea, vomiting, diarrhea, abdominal pain and constipation.”